The Associations of Naturalistic Classic Psychedelic Use, Mystical Experience, and Creative Problem Solving
This study (n=68) found that having a mystical experience during psychedelic use is correlated with quicker completion times on a measure of creativity (completion time of Duncker's Candle Problem). The number of mystical experiences was not correlated with completion time.
Authors
- Peter Hendricks
Published
Abstract
Developing methods for improving creativity is of broad interest. Classic psychedelics may enhance creativity; however, the underlying mechanisms of action are unknown. This study was designed to assess whether a relationship exists between naturalistic classic psychedelic use and heightened creative problem-solving ability and if so, whether this is mediated by lifetime mystical experience. Participants (N = 68) completed a survey battery assessing lifetime mystical experience and circumstances surrounding the most memorable experience. They were then administered a functional fixedness task in which faster completion times indicate greater creative problem-solving ability. Participants reporting classic psychedelic use concurrent with mystical experience (n = 11) exhibited significantly faster times on the functional fixedness task (Cohen’s d = -.87; large effect) and significantly greater lifetime mystical experience (Cohen’s d = .93; large effect) than participants not reporting classic psychedelic use concurrent with mystical experience. However, lifetime mystical experience was unrelated to completion times on the functional fixedness task (standardized β = -.06), and was therefore not a significant mediator. Classic psychedelic use may increase creativity independent of its effects on mystical experience. Maximizing the likelihood of mystical experience may need not be a goal of psychedelic interventions designed to boost creativity.
Research Summary of 'The Associations of Naturalistic Classic Psychedelic Use, Mystical Experience, and Creative Problem Solving'
Introduction
Creative cognition is of broad interest and has been explored with cognitive, behavioural, and pharmacologic approaches. Earlier research shows mixed results for stimulant and alcohol effects on creativity, and findings for cannabis and classic psychedelics (such as DMT, LSD, mescaline, and psilocybin) are equivocal but sometimes promising. Classic psychedelics produce altered self-awareness and mystical-type experiences characterised by awe, ineffability, and feelings of unity, and contemporary clinical studies often link therapeutic benefits to the intensity of psychedelic-occasioned mystical experience. Because modern psychedelic-assisted therapies typically aim to maximise mystical experience, understanding whether mystical experience mediates any enhancement in creativity would inform how interventions should be designed. This study, by Sweat and colleagues, tested whether naturalistic classic psychedelic use is associated with improved creative problem-solving ability and whether any such association is mediated by lifetime mystical experience. The investigators hypothesised that psychedelic use would relate to greater lifetime mystical experience, which in turn would predict better performance on a functional fixedness task (Duncker’s Candle Problem). The study uses a naturalistic, non-randomised design to probe these associations in a sample drawn from a university and local community.
Expert Research Summaries
Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.
Study Details
- Study Typeindividual
- Journal
- Topic
- Author
- APA Citation
Sweat, N. W., Bates, L. W., & Hendricks, P. S. (2016). The Associations of Naturalistic Classic Psychedelic Use, Mystical Experience, and Creative Problem Solving. Journal of Psychoactive Drugs, 48(5), 344-350. https://doi.org/10.1080/02791072.2016.1234090
References (23)
Papers cited by this study that are also in Blossom
Baggot, M. J. · Preprints (2015)
Bogenschutz, M. P., Forcehimes, A. A., Pommy, J. A. et al. · Journal of Psychopharmacology (2015)
Bogenschutz, M. P., Johnson, M. W. · Progress in Neuro-Psychopharmacology and Biological Psychiatry (2016)
Rodríguez-Fornells, A., Ribeiro, S., Sanches, R. F. et al. · European Neuropsychopharmacology (2015)
Carhart-Harris, R. L., Bolstridge, M., Rucker, J. et al. · Lancet Psychiatry (2016)
Carhart-Harris, R. L., Leech, R., Shanahan, M. et al. · Frontiers in Human Neuroscience (2014)
Garcia-Romeu, A., Griffiths, R. R., Johnson, M. W. · Current Drug Abuse Reviews (2015)
Gasser, P., Holstein, D., Michel, Y. et al. · Journal of Nervous and Mental Disease (2014)
Griffiths, R. R. · Journal of Psychopharmacology (2008)
Griffiths, R. R., Richards, W. A., Mccann, U. et al. · Journal of Psychopharmacology (2006)
Show all 23 referencesShow fewer
Grob, C. S., Danforth, A. L., Chopra, G. S. et al. · JAMA Psychiatry (2011)
Harman, W. W., McKim, R. H., Mogar, R. E. et al. · Psychological Reports (1966)
Hendricks, P. S., Clark, B., Johnson, M. W. et al. · Journal of Psychopharmacology (2014)
Hendricks, P. S., Thorne, C. B., Clark, B. et al. · Journal of Psychopharmacology (2015)
Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P. et al. · Journal of Psychopharmacology (2014)
Johnson, M. W., Richards, W. A., Griffiths, R. R. · Journal of Psychopharmacology (2008)
Jones, J. A., Blagrove, M., Parrott, A. C. · Journal of Psychoactive Drugs (2009)
Kuypers, K. P. C., Riba, &. J., De La Fuente Revenga, &. M. et al. · Psychopharmacology (2016)
Maclean, K. A., Johnson, M. W., Griffiths, R. R. · Journal of Psychopharmacology (2011)
King, C., Nichols, D. E. · Nature Reviews Neuroscience (2013)
Sessa, B. · Journal of Psychopharmacology (2008)
Tylš, F., Páleníček, T., Horacek, J. · European Neuropsychopharmacology (2013)
Vollenweider, F. X., Kometer, M. · Nature Reviews Neuroscience (2010)
Cited By (13)
Papers in Blossom that reference this study
Dourron, H. M., Strauss, C., Hendricks, P. S. · Pharmacological Reviews (2022)
Forstmann, M., Sagioglou, C. · European Psychologist (2022)
Qiu, X., Minda, J. P. · Psyarxiv (2021)
Rodríguez Arce, J. M., Winkelman, M. J. · Frontiers in Psychology (2021)
Kočárová, C., Horacek, J., Carhart-Harris, R. L. · Frontiers in Psychiatry (2021)
Nichols, D. E., Walter, H. · Pharmacopsychiatry (2020)
Silver, L. S. · American Journal of Management (2020)
Andersson, M., Kjellgren, A. · Harm Reduction Journal (2019)
Jungaberle, H., Thal, S., Zeuch, A. et al. · Neuropharmacology (2018)
Swanson, L. R. · Frontiers in Pharmacology (2018)
Show all 13 papersShow fewer
Johnstad, P. G. · Nordic Studies on Alcohol and Drugs (2018)
Kraehenmann, R. · Current Neuropharmacology (2017)
Kraehenmann, R. ;., Pokorny, D. ;., Vollenweider, L. ;. et al. · Psychopharmacology (2017)
Your Personal Research Library
Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.